MAHA Stack
82
síntesis
3
2,600
intermediate
May 17, 2026
Visión General
The MAHA Stack — inspired by RFK Jr.''s "Make America Healthy Again" movement and his public advocacy for peptide access — combines three of the most evidence-backed peptides into a foundational health optimization protocol covering healing, immunity, and cognitive function. After HHS Secretary RFK Jr.'s February 2026 signal of intent to reconsider the restricted peptide list — followed by the FDA formally removing 12 peptides from the Category 2 list in April 2026 (removal is not the same as approval, and the peptides remain under PCAC review) — this combination became one of the most searched peptide stacks online. BPC-157 provides systemic healing support — gut mucosal repair, connective tissue regeneration, anti-inflammatory action, and neurotropic effects across the gut-brain axis. Its broad mechanism makes it a foundational health compound rather than a specialized treatment. Thymosin Alpha-1 is an immune modulator originally isolated from the thymus gland. Unlike crude immune "boosters," it precisely calibrates immune function — enhancing the response against pathogens and abnormal cells while reducing excessive inflammatory signaling that drives autoimmune-type conditions. It activates dendritic cells, NK cells, and T-helper cells while modulating cytokine production. Thymosin Alpha-1 has FDA-approved use in some countries for hepatitis and is extensively studied for chronic fatigue, autoimmune conditions, and cancer immunotherapy support. Semax adds the cognitive and neural component — BDNF upregulation, dopaminergic support, and neuroprotection. This is consistent with the MAHA movement''s emphasis on brain health and cognitive function as core components of overall health. Together, this stack represents a "whole-system" approach: healing the body''s physical tissue, calibrating immune function, and supporting the brain — the three systems most impacted by modern inflammatory lifestyles.
Protocolo de Dosis
250 mcg
por dosis
1,500 mcg
por dosis
600 mcg
por dosis
Objetivos & Evidencia
Advertencias
- BPC-157 was removed from FDA Category 2 (April 2026) but remains under PCAC review (July 23, 2026) — not legal to compound yet. Stack peptides individually before combining if new to peptide therapy.
Comments
Sign in to join the discussion
Aviso: Este stack es subido por la comunidad y solo tiene fines de investigación. Peptide Contacts no verifica la seguridad o eficacia de los stacks subidos. Siempre consulte a un profesional de la salud calificado antes de usar cualquier protocolo de péptidos.